Saturday 17 October 2026
Export XLO’s income statement to Excel — free account
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, up 589.9% from fiscal 2024. In the quarter to June 2026, revenue grew 131.2%, EPS grew 85.3% and free cash flow fell 26.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
8.77
0.25
−2.77%
Follow XLO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | — | — | — | — |
Altman Z-Score |
(3.34) | (9.15) | — | — | — | — | — | — |
P/S ratio |
1.71 | 0.00 | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(6.58) | (19.94) | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | — | — | — | — | — |
P/Operating CF |
(37.49) | (3.61) | — | — | — | — | — | — |
P/B ratio |
2.12 | 2.90 | — | — | — | — | — | — |
Price to Tangible BV |
2.12 | 2.90 | — | — | — | — | — | — |
EV/Sales |
(1.40) | 0.00 | — | — | — | — | — | — |
EV/EBITDA |
1.51 | 0.04 | — | — | — | — | — | — |
EV/Operating CF |
12.24 | 0.14 | — | — | — | — | — | — |
EV/FCF |
11.09 | 0.14 | — | — | — | — | — | — |
Quick Ratio |
2.53 | 2.03 | 2.80 | 5.70 | 15.50 | 0.87 | 9.38 | — |
Current Ratio |
2.58 | 2.21 | 3.02 | 5.90 | 15.85 | 0.93 | 9.81 | — |
Net Debt/EBITDA |
3.40 | 0.94 | 0.58 | 1.34 | 2.56 | 0.22 | 1.61 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 2.27% | 4.42% | 20.41% | 29.70% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.03 | 0.05 | (1.40) | 0.48 | — |
Asset Turnover |
0.39 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.14 | 0.32 | 0.90 | 0.86 | 1.07 | 0.65 | 1.04 | — |
Capex/Depreciation |
(0.34) | (0.02) | (0.26) | (1.01) | (0.73) | (2.05) | 0.00 | — |
| (132.53%) | (214.02%) | (107.25%) | (60.62%) | (148.42%) | 97.90% | 30.69% | — | |
| (31.04%) | (88.24%) | (76.37%) | (49.39%) | (59.60%) | (111.51%) | (55.20%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(37.82%) | (155.54%) | (200.47%) | (79.74%) | (38.41%) | (951.72%) | (31.04%) | — |
Average Days of Receivables |
41.70 | 0.00 | — | — | — | — | — | — |
Research and Development Expense of Revenue |
128.04% | 649.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
67.88% | 390.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
15.85% | 101.42% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Graham Net Nets |
0.34 | 0.13 | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | — | — | — | — | — | — |
Earnings Yield |
(59.63%) | (134.08%) | — | — | — | — | — | — |
Free Cash Flow Yield |
(7.36%) | (36.03%) | — | — | — | — | — | — |
Revenue per Share |
5.24 | 1.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.60) | (4.81) | (34.95) | (38.72) | (201.73) | (965.00) | (0.66) | — |
Capex per Share |
(0.06) | (0.01) | (0.25) | (0.95) | (2.75) | (58.50) | 0.00 | — |
Free Cash Flow per Share |
(0.66) | (4.82) | (35.20) | (39.67) | (204.47) | (1,023.50) | (0.66) | — |
Cash per Share |
16.45 | 14.47 | 22.77 | 61.55 | 494.76 | 514.39 | 1.78 | — |
Shareholders Equity per Share |
4.22 | 4.60 | 18.76 | 54.02 | 463.23 | (141.31) | 1.40 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
4.22 | 4.60 | 18.76 | 54.02 | 463.23 | (141.31) | 1.40 | — |
Free Cash Flow |
(5.51) | (18.41) | (69.11) | (77.59) | (81.85) | (38.28) | (18.03) | — |
Working Capital |
88.75 | 32.97 | 32.17 | 103.38 | 189.74 | (1.56) | 45.90 | — |
Capital Expenditures |
(0.52) | (0.04) | (0.49) | (1.87) | (1.10) | (2.19) | (0.71) | — |
Net Current Asset Value |
25.62 | 6.76 | 24.03 | 90.98 | 169.89 | (21.01) | 26.89 | — |
EV/EBIT |
1.46 | 0.04 | — | — | — | — | — | — |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | — | — | — | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.40 | 0.37 | 0.32 | 0.25 | 0.20 | 0.14 | 0.02 | — |
Cash ROIC |
(3.19%) | (25.26%) | (84.76%) | (33.85%) | (20.82%) | (179.17%) | (17.01%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,829.46 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
2.87 | 1.81 | 2.09 | 3.13 | 4.29 | 3.98 | 3.98 | — |
Average Assets |
112.88 | 66.00 | 100.05 | 178.61 | 127.19 | 49.52 | 31.36 | — |
Average Common Equity |
26.44 | 27.21 | 71.24 | 145.54 | 51.07 | (56.40) | (56.40) | — |
Columns are period end dates